Table 3.
Clinicopathological findings of IgG subclass deposit on TBM
| None (n = 47) | Isotype (n = 40) | Mixed (n = 21) | P Value | |
|---|---|---|---|---|
| Male (%) | 68.1 | 70.0 | 81.0 | 0.542 |
| Age (year) | 52.7 ± 9.7 | 54.9 ± 9.0 | 54.0 ± 9.2 | 0.556 |
| Duration of diabetes (mo) | 96.0 (45.0, 156.0) | 96.0 (27.0, 120.0) | 114.0 (36.0, 120.0) | 0.816 |
| Duration of nephropathy (mo) | 6.0 (1.0, 24.0) | 1.0 (1.0, 6.0) | 2.0 (1.0, 6.0) | 0.023 |
| Proteinuria(g/24 h) | 2.9 (0.6, 7.0) | 3.8 (0.9, 6.0) | 6.6 (3.3, 8.2) | 0.108 |
| Albumin (g/L) | 32.4 ± 8.0 | 32.0 ± 6.5 | 27.8 ± 5.0 | 0.035 |
| Scr(μmol/L) | 101.0 (71.5, 145.5) | 118.0 (82.4, 153.8) | 110.0 (76.0, 164.4) | 0.482 |
| eGFR (ml/min/1.73m2) | 65.0 (42.0, 114.0) | 65.5 (35.6, 97.9) | 61.0 (27.0, 104.3) | 0.569 |
| DN stage I [n(%)] | 4 (8.5) | 4 (10.0) | 0 (0) | 0.450 |
| DN stage II [n(%)] | 11 (23.4) | 10 (25.0) | 5 (23.8) | 1.000 |
| DN stage III [n(%)] | 29 (61.7) | 25 (62.5) | 16 (76.2) | 0.523 |
| DN stage IV [n(%)] | 3 (6.4) | 1 (2.5) | 0 (0) | 0.530 |
| IgG intensity | 1.3 ± 0.6 | 1.2 ± 0.4 | 1.2 ± 0.4 | 0.538 |
| C3 intensity | 0.0 (0.0, 0.5) | 0.0 (0.0, 0.0) | 0.0 (0.0, 0.5) | 0.880 |
| GS (%) | 17.0 (10.0, 32.4) | 24.4 (10.0, 40.0) | 14.2 (8.0, 24.5) | 0.398 |
| CD34 + area (%) | 25.4 ± 9.2 | 22.8 ± 7.3 | 25.0 ± 7.0 | 0.309 |
| GBM thickness (nm) | 754.7 ± 180.8 | 747.3 ± 165.8 | 731.3 ± 203.3 | 0.899 |
| FPE | 2.6 ± 0.6 | 2.7 ± 0.7 | 2.8 ± 0.4 | 0.524 |
| IFTA score | 2.0 ± 0.6 | 2.1 ± 0.6 | 1.9 ± 0.8 | 0.410 |
| KIM-1 + area (%) | 20.0 (10.0, 30.0) | 30.0 (20.0, 40.0) | 30.0 (20.0, 50.0) | 0.008 |
| TBM thickness (nm) | 1067.9 ± 282.4 | 1320.5 ± 365.4 | 1381.0 ± 570.1 | 0.001 |
| Inter-infla score | 2.0 (2.0, 2.0) | 2.0 (2.0, 3.0) | 2.0 (1.0, 2.5) | 0.484 |
| Hyalinosis score | 1.8 ± 0.4 | 1.7 ± 0.5 | 1.7 ± 0.5 | 0.331 |
| A-sclerosis score | 1.0 (0.0, 1.0) | 1.0 (0.0, 1.0) | 1.0 (0.5, 1.0) | 0.519 |
TBM, tubular basement membrane; Scr, serum creatinine; eGFR, estimated glomerular filtration rate; DN, diabetic nephropathy; GS, Glomerular sclerosis; FPE, foot process effacement; IFTA, interstitial fibrosis and tubular atrophy; KIM-1, kidney injury molecular-1; TBM, tubular basement membrane; Inter-infla, interstitial inflammation; A-sclerosis score, Arteriosclerosis score